NRM-823 / Normunity - LARVOL DELTA

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Normunity AccelCo, Inc. | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Monotherapy • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors (GlobeNewswire) - "Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors."

Trial status • Solid Tumor

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Normunity AccelCo, Inc.

Checkpoint inhibition • Monotherapy • New P1 trial • Cervical Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms (Businesswire) - "Normunity...announced that it has closed a Series B financing for $75 million....Proceeds from the financing will be used to advance Normunity’s lead program, NRM-823, a first-in-class T cell engager that binds a novel, highly specific tumor target expressed on multiple types of solid tumors. The company plans to initiate the Phase 1 clinical trial of NRM-823 in 2H 2025 and leverage its prior work by advancing other modalities against this tumor-specific target, including antibody‑drug conjugates and radiotheranostics. The funding will also be used to advance Normunity’s pipeline of programs that address novel targets responsible for tumor-specific immune suppression."

Financing • New P1 trial • Oncology • Solid Tumor